Page 182 - 80_01
P. 182
Basilio
Colligris,
Jesús
Pintor
90. Barnes TM, Hou J, King BM. Chimeric IL-1 receptor type I agonists and
antagonists. WO2012016203 (2012)
91. Furfine ES, Hou J, Collins K, et al., editors. EBI-005: an Interleukin-1 Receptor
Inhibitor Designed for the Treatment of Dry Eye Syndrome, 2012 Poster:
2340/A3572012.
92. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in
acute gout. Arthritis Res Ther. 9(2), R28 (2007).
93. Fel A, Aslangul E, Le Jeunne C. (Eye and corticosteroid's use). Presse Med.
41(4), 414-21 (2012).
94. Carracedo G, Peral A, Pintor J. Diadenosine polyphosphates in tears of Sjogren
syndrome patients. Invest Ophthalmol Vis Sci. 51(11), 5452-9 (2010).
95. Pintor J. (A molecular marker for dry eye). Arch Soc Esp Oftalmol. 82(3), 129-
30 (2007).
96. McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Surv Ophthalmol.
57(4), 293-316 (2012).
97. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and
management of dry eye disease. Am J Ophthalmol. 151(5), 792-8 e1 (2011).
178
